Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019.
- Resource Type
- Article
- Authors
- Buonomo, Antonio Riccardo; Filippo, Isabella Di; Esposito, Nunzia; Saccone, Gabriele; Nobile, Mariano; Viceconte, Giulio; Villari, Riccardo; Carlo, Costantino Di; Bifulco, Giuseppe; Gentile, Ivan
- Source
- American Journal of Perinatology. Feb2024, Vol. 41 Issue 3, p365-367. 3p.
- Subject
- *COVID-19
*INTRAVENOUS therapy
*POST-acute COVID-19 syndrome
*MONOCLONAL antibodies
*ANTIVIRAL agents
*PREGNANT women
*SEVERITY of illness index
*TREATMENT effectiveness
*VACCINATION status
*OUTPATIENT services in hospitals
*DISEASE risk factors
*PREGNANCY
- Language
- ISSN
- 0735-1631
Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate COVID-19 treated with casirivimab/imdevimab. Results Twelve unvaccinated pregnant patients with mild-to-moderate COVID-19 received casirivimab/imdevimab at the dose of 1200/1200 mg by intravenous infusion over 60 minutes. All women were managed outpatient. None experienced severe adverse drug reaction and none progressed to severe disease. Conclusion Casirivimab/imdevimab should be considered for outpatient treatment of unvaccinated pregnant women with mild-to-moderate COVID-19 to decrease the risk of severe disease. Key Points Casirivimab/imdevimab is not well studied in pregnant women. Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 decreases the risk of severe disease. Casirivimab/imdevimab in pregnant women with mild-to-moderate COVID-19 is well tolerated. [ABSTRACT FROM AUTHOR]